QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:PHVS

Pharvaris - PHVS Stock Forecast, Price & News

$2.26
+0.23 (+11.36%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.02
▼
$2.78
50-Day Range
$1.98
▼
$7.98
52-Week Range
$1.77
▼
$27.50
Volume
483,624 shs
Average Volume
24,867 shs
Market Capitalization
$71.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Pharvaris MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
631.7% Upside
$16.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.11) to ($2.25) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

890th out of 1,023 stocks

Pharmaceutical Preparations Industry

438th out of 501 stocks

See Top Rated MarketRank™ Stocks Here
PHVS stock logo

About Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

PHVS Stock News Headlines

December 3, 2022 | reuters.com
PHVS.OQ - Pharvaris NV | Stock Price & Latest News | Reuters
November 27, 2022 | americanbankingnews.com
Pharvaris (NASDAQ:PHVS) Receives $16.50 Average Target Price from Analysts
November 10, 2022 | finance.yahoo.com
Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
October 7, 2022 | finance.yahoo.com
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
September 30, 2022 | finance.yahoo.com
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
September 17, 2022 | benzinga.com
Pharvaris Highlights Data Supporting Clinical...
September 16, 2022 | finance.yahoo.com
Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium
September 14, 2022 | uk.investing.com
Pharvaris Reports Q2 Results, Provides Business Update
September 13, 2022 | benzinga.com
Pharvaris Reports Second Quarter 2022 Financial...
September 12, 2022 | finance.yahoo.com
Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
August 24, 2022 | seekingalpha.com
Pharvaris downgraded at BofA after FDA clinical hold on HAE candidate
August 23, 2022 | seekingalpha.com
Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
August 22, 2022 | finance.yahoo.com
Why Pharvaris Shares Are Plummeting Today?
August 22, 2022 | markets.businessinsider.com
Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday's Mid-Day Session
August 22, 2022 | finance.yahoo.com
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
August 20, 2022 | uk.finance.yahoo.com
Pharvaris N.V. (PHVS)
July 14, 2022 | finance.yahoo.com
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference
July 6, 2022 | finance.yahoo.com
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
June 22, 2022 | uk.finance.yahoo.com
Pharvaris NV share price hits a one-year high
June 7, 2022 | finance.yahoo.com
Pharvaris Participates in the Kinin 2022 Conference
May 16, 2022 | finance.yahoo.com
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)
May 13, 2022 | seekingalpha.com
Pharvaris GAAP EPS of -€0.48
May 11, 2022 | investing.com
Pharvaris Reports Q1 EPS of EUR ($0.48), Provides Business Highlights
May 11, 2022 | finance.yahoo.com
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 11, 2022 | finance.yahoo.com
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
See More Headlines
Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

PHVS Company Calendar

Last Earnings
9/12/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHVS
CUSIP
N/A
CIK
1830487
Web
www.pharvaris.com
Phone
31-71-203-6410
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+631.7%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-50,560,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-24.67%
Return on Assets
-23.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.85
Quick Ratio
12.85

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.62 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
31,840,000
Free Float
N/A
Market Cap
$71.80 million
Optionable
Not Optionable
Beta
-0.77

Key Executives

  • Mr. Berndt Axel Edvard Modig CPA (Age 63)
    M.B.A., MBA, Co-Founder, CEO & Exec. Director
  • Ms. Anna Nijdam M.Sc. (Age 41)
    R.A., Head of Fin. & Principal Accounting Officer
  • Dr. Jochen Knolle Ph.D. (Age 72)
    Chief Scientific Officer & COO
  • Ms. Joan Schmidt J.D. (Age 58)
    Chief Legal Officer
  • Maryann Cimino
    Director of Corp. Relations
  • Ms. Annick Deschoolmeester
    Chief HR Officer
  • Dr. Peng Lu M.D. (Age 44)
    Ph.D., Chief Medical Officer
  • Dr. Anne Lesage Ph.D. (Age 61)
    Chief Early Devel. Officer
  • Dr. Morgan Conn Ph.D. (Age 53)
    Chief Bus. Officer
  • Mr. Wim Souverijns Ph.D. (Age 51)
    Chief Community Engagement & Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PHVS Stock - Frequently Asked Questions

Should I buy or sell Pharvaris stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PHVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHVS, but not buy additional shares or sell existing shares.
View PHVS analyst ratings or view top-rated stocks.

What is Pharvaris' stock price forecast for 2023?

5 analysts have issued 12 month price objectives for Pharvaris' shares. Their PHVS share price forecasts range from $10.00 to $22.00. On average, they predict the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 631.7% from the stock's current price.
View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts.

How have PHVS shares performed in 2022?

Pharvaris' stock was trading at $14.39 on January 1st, 2022. Since then, PHVS shares have decreased by 84.3% and is now trading at $2.2550.
View the best growth stocks for 2022 here.

How were Pharvaris' earnings last quarter?

Pharvaris (NASDAQ:PHVS) announced its earnings results on Monday, September, 12th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.15.

When did Pharvaris IPO?

(PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

What is Pharvaris' stock symbol?

Pharvaris trades on the NASDAQ under the ticker symbol "PHVS."

Who are Pharvaris' major shareholders?

Pharvaris' stock is owned by many different institutional and retail investors. Top institutional investors include Cormorant Asset Management LP (3.79%), Pictet Asset Management SA (1.26%) and Tower Research Capital LLC TRC (0.01%).

How do I buy shares of Pharvaris?

Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharvaris' stock price today?

One share of PHVS stock can currently be purchased for approximately $2.26.

How much money does Pharvaris make?

Pharvaris (NASDAQ:PHVS) has a market capitalization of $71.80 million. The company earns $-50,560,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How can I contact Pharvaris?

The official website for the company is www.pharvaris.com. The company can be reached via phone at 31-71-203-6410 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:PHVS) was last updated on 12/6/2022 by MarketBeat.com Staff